德国RABBIT-SpA登记研究中难治性与治疗抵抗性中轴型脊柱关节炎的频率
基于德国RABBIT-SpA前瞻性多中心纵向登记研究,在881例未使用过生物制剂或靶向合成DMARD的中轴型脊柱关节炎患者中,8.5%符合ASAS难治性(D2M)定义,2.5%进一步符合治疗抵抗性(TR)定义;D2M患者更多为女性、HLA-B27阴性并伴关节炎和附着点炎,TR患者炎症表现更明显。
要点
- 881例中8.5%符合D2M、2.5%符合TR,提示真实世界中存在临床相关亚群
- D2M患者女性更多、HLA-B27阴性更多、关节炎与附着点炎更多,客观炎症指标较少
- TR患者更多见骶髂关节/脊柱MRI病变和CRP升高,外周关节炎较少
核心结论
- 在大型真实世界队列中应用ASAS定义可识别出具有临床意义的D2M和TR亚群,支持其临床实用性,并提示需要针对不同表型制定管理策略。
研究设计与样本
- 数据来自正在进行的德国RABBIT-SpA前瞻性、多中心、纵向登记研究。
- 纳入标准为未使用过生物制剂和靶向合成DMARD(b/tsDMARD)、已启动b/tsDMARD且随访≥12个月的患者。
- 应用ASAS新提出的D2M和TR定义识别病例。
主要发现
- 1850例axSpA患者中881例(48%)在观察开始时未使用过b/tsDMARD。
- 881例中75例(8.5%)符合ASAS的D2M标准,其中22例(2.5%)进一步符合TR标准。
- 基线时D2M患者较非D2M患者更多为女性、更多HLA-B27阴性、更多伴关节炎和附着点炎,且CRP升高或MRI病变等客观炎症标志物较少。
- D2M患者阿片类药物使用高于非D2M患者。
- TR组较D2M/非TR组女性和肥胖比例更低,但即使启动一线b/tsDMARD时也更多见骶髂关节/脊柱MRI病变和CRP升高等炎症征象,外周关节炎较少。
关键数值与推荐
- D2M:75/881(8.5%);TR:22/881(2.5%),均按ASAS新定义判定。
- 观察开始时未使用过b/tsDMARD者占1850例axSpA患者的881例(48%)。
临床怎么用
- 对启动首个b/tsDMARD的axSpA患者可按ASAS定义评估D2M与TR状态以识别难治亚群。
- D2M患者客观炎症指标较少且阿片类使用较多,提示需关注疼痛与表型特异性管理。
- TR患者炎症征象更明显,提示需加强炎症控制与影像/CRP监测。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the frequency of axial SpA (axSpA) patients fulfilling the recently proposed Assessment of SpondyloArthritis International Society (ASAS) definitions for difficult-to-manage (D2M) and treatment-refractory (TR) axSpA, and to characterize these patients at initiation of their first advanced therapy. METHODS: Data were derived from the ongoing prospective, multicentre, longitudinal German RABBIT-SpA registry. Patients were eligible if they were biologic and targeted synthetic (b/ts) DMARD-naïve, had initiated a b/tsDMARD and had ≥12 months of follow-up. ASAS definitions were applied to identify cases of D2M and TR. RESULTS: Of 1850 patients with axSpA, 881 (48%) were b/tsDMARD-naïve at the start of observation. A total of 75/881 patients (8.5%) fulfilled the ASAS criteria for D2M and 22/881 (2.5%) additionally met the criteria for TR. At baseline, D2M patients were more frequently female, more often HLA-B27-negative, and more commonly presented with arthritis and enthesitis compared with not-D2M (nD2M) patients. In addition, they exhibited fewer objective inflammatory markers such as elevated CRP or MRI lesions. Opioid use was higher across D2M patients compared with nD2M patients. In the TR group compared with the D2M/nTR, the proportion of female and of obesity was lower. Even at initiation of first-line b/tsDMARD, these patients showed more frequently signs of inflammation, including sacroiliac/spinal MRI lesions and elevated CRP, while peripheral arthritis was less frequent. CONCLUSION: Applying the ASAS definitions in a large real-world cohort identified clinically relevant subgroups with D2M and TR. These findings support their clinical utility and highlight the need for phenotype-specific management strategies.
引用
- Proft F, Lembke S, Weiß A, et al. Frequency of difficult-to-manage and treatment-refractory axial SpA: insights from the German RABBIT-SpA register using recent ASAS definitions. Rheumatology (Oxford). 2026. PMID: 41335412. doi:10.1093/rheumatology/keaf641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。